Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets

This publication has 37 references indexed in Scilit:

• Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine
  PLOS ONE, 2008
• Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research
  Vaccine, 2007
• Antiviral Resistance and the Control of Pandemic Influenza
  PLoS Medicine, 2007
• Antiviral Management of Seasonal and Pandemic Influenza
  The Journal of Infectious Diseases, 2006
• Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
  The Lancet, 2006
• Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene
  Clinical and Vaccine Immunology, 2006
• Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy
  The Journal of Infectious Diseases, 2005
• Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
  Vaccine, 2005
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
  The Lancet, 2001
• Cytotoxic T-Cell Immunity to Influenza
  New England Journal of Medicine, 1983